Sunday, 22 Nov 2026 Breaking: Spain’s Pedro Sanchez ups the ante as snap poll approaches on November 29
BREAKING: Apple launches AI platform | Tesla earnings beat estimates | Nvidia stock surges | Bitcoin crosses major resistance
Business

Healthcare stocks slide after SC questions wide gap between retailer and consumer medicine prices

Healthcare stocks slide after SC questions wide gap between retailer and consumer medicine prices

Mumbai (Maharashtra) [India], September 30 (ANI): Healthcare and pharmaceutical stocks came under pressure on Wednesday, with the Nifty Healthcare index falling 424.90 points, or 2.57 per cent, to 16,137.75, a day after the Supreme Court questioned the wide gap between the prices charged to retailers and the prices paid by consumers for medicines.
The decline was broad-based across the healthcare index, with 19 of the 20 stocks shown in the index trading in the red. Laurus Labs was the only stock in positive territory, gaining 0.05 per cent.
Among the major decliners, Fortis Healthcare fell 6.33 per cent, while Apollo Hospitals declined 5.70 per cent and Max Healthcare dropped 5.33 per cent. Glenmark Pharmaceuticals was down 4.37 per cent.
Other major pharmaceutical stocks also witnessed losses. Zydus Lifesciences declined 3.21 per cent, KIMS fell 3.23 per cent, Sun Pharma dropped 2.60 per cent, Cipla declined 2.41 per cent, Torrent Pharma fell 1.92 per cent, and Biocon was down 1.78 per cent.
The broad-based fall came after the Supreme Court on Tuesday asked the Centre whether a uniform cap should be imposed on retail prices of medicines and medical devices to prevent excessive markups over the price charged to retailers.
A bench of Justices Vikram Nath and Sandeep Mehta questioned why the Maximum Retail Price, or MRP, could not be restricted to 16 per cent above the Price To Retailer, or PTR, particularly in cases involving life-saving medicines.
The court also raised concerns over the wide difference between the price at which medicines are supplied to retailers and the maximum price at which they are sold to consumers.
Justice Sandeep Mehta cited the example of a cancer drug priced at about Rs 27,000 for consumers despite its price to retailers being around Rs 3,000, and said the disparity warranted scrutiny.
The Supreme Court also questioned the rationale for keeping non-scheduled medicines outside the price-control regime under the Drugs (Prices Control) Order, 2013.
The bench further noted that high medicine prices could have an impact on public funds when patients receive treatment under government health schemes such as Ayushman Bharat, particularly when hospitals require medicines to be purchased from their in-house pharmacies.
Solicitor General Tushar Mehta, appearing for the Centre, said a balance would have to be worked out while acknowledging the concerns raised by the petitioners.
The matter is scheduled to be heard again on October 12. (ANI)

Tags

Related News

Deposit costs, loan resets could drive uneven bank margins in December quarter
Business
Deposit costs, loan resets could drive uneven bank margins in December quarter

<p>New Delhi [India], November 22 (ANI): Banks could see their net interest margins move in different directions in the...

Gram Panchayats swing to Rs 6,920 crore deficit in FY25 as receipts fall, RBI report shows
Business
Gram Panchayats swing to Rs 6,920 crore deficit in FY25 as receipts fall, RBI report shows

<p>New Delhi [India], November 22 (ANI): Gram Panchayats across 25 states recorded a combined deficit of Rs 6,920 crore...

CAIT credits PM Modi’s appeal for nearly 40% fall in gold import bill
Business
CAIT credits PM Modi’s appeal for nearly 40% fall in gold import bill

<p>New Delhi [India], November 22 (ANI): India’s gold import bill fell by USD 16.46 billion, or nearly 40 per cent, in A...

Maruti Suzuki hikes prices of select models by about 0.31% on average
Business
Maruti Suzuki hikes prices of select models by about 0.31% on average

<p>New Delhi [India], November 22 (ANI): Maruti Suzuki India raised prices of select models from Sunday, citing sustaine...

Rising government debt unlikely to trigger broad sovereign crisis in 2027: UBS
Business
Rising government debt unlikely to trigger broad sovereign crisis in 2027: UBS

<p>New Delhi [India], November 22 (ANI): Rising government borrowing and higher debt-servicing costs are expected to rem...

Asia, Africa to drive expansion of India's export markets as shipments grow across regions
Business
Asia, Africa to drive expansion of India's export markets as shipments grow across regions

<p>New Delhi [India], November 22 (ANI): India’s merchandise exports are gaining a wider geographical footprint, with st...